June 2017
Volume 58, Issue 8
ARVO Annual Meeting Abstract  |   June 2017
One-year safety outcomes of intravitreal implant of fluocinolone acetonide 0.19 mg in clinical practice assessed by intraocular pressure measurement
Author Affiliations & Notes
  • António Figueiredo
    Ophthalmology, ALM Oftalmolaser, Lisbon, Portugal
  • José António Dias
    Ophthalmology, Joaquim Chaves Saúde, Lisbon, Portugal
  • Carlos Marques-Neves
    Ophthalmology, ALM Oftalmolaser, Lisbon, Portugal
    Ophthalmology, Hospital de Santa Maria. Faculty of Medicine, University of Lisbon, Lisbon, Portugal
  • Rufino Silva
    Ophthalmology, Coimbra Hospital and University Center (CHUC); Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal
    Ophthalmology, Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal
  • Angelina Meireles
    Ophthalmology, Centro Hospitalar do Porto - Hospital Santo António, Porto, Portugal
  • Footnotes
    Commercial Relationships   António Figueiredo, Alimera Sciences (C); José António Dias, None; Carlos Marques-Neves, None; Rufino Silva, Alcon (C), Alimera Sciences (C), Allergan (C), Bayer (C), Novartis (C), Thea (C); Angelina Meireles, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 90. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      António Figueiredo, José António Dias, Carlos Marques-Neves, Rufino Silva, Angelina Meireles; One-year safety outcomes of intravitreal implant of fluocinolone acetonide 0.19 mg in clinical practice assessed by intraocular pressure measurement. Invest. Ophthalmol. Vis. Sci. 2017;58(8):90.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The use of intravitreal corticosteroids (IVT) in the treatment of diabetic macular edema (DME) increased in recent years. A common complication of intravitreal steroids is secondary ocular hypertension (OHT), which can occur immediately as a consequence of increased intraocular volume or later due to increased outflow resistance. Most cases of OHT are clinically manageable. The aim of this study was to determine rise of intraocular pressure (IOP) in DME patients treated with fluocinolone acetonide (FAc) 0.19 mg intravitreal injection.

Methods : 107 FAc-treated eyes of 92 diabetic patients with chronic DME were analyzed retrospectively. IOP was assessed at baseline, week 2-4, month 3, month 6, month 9, and 1 year after FAc implantation. All patients included in this study, which adhered to the tenets of the Declaration of Helsinki, gave their informed consent.

Results : At baseline mean IOP was 15.59 mmHg ± 3.50 (mean ± standard deviation). At week 2-4, month 1, 3, 6, 9 and month 12 it was observed an IOP value of 16.37 mmHg ± 4.06 (mean ± standard deviation), 17.61 mmHg ± 4.87 (mean ± standard deviation), 16.19 mmHg ± 3.81 (mean ± standard deviation), 18.00 mmHg ± 4.63 (mean ± standard deviation), and 18.00 mmHg ± 5.20 (mean ± standard deviation), respectively (p <.0001). The mean IOP change from baseline to 3, 6, 9 months and 1 year was 0.8, 2.1, 0.8, 2.2 and 1.9mmHg, respectively. At baseline, 75% of patients reported as not taking IOP lowering medication vs. 25% of patients who were already taking medication for this indication. At the end of the 12-month follow-up, 15% of the patients started IOP lowering medication. No patients required incisional surgery for OHT.

Conclusions : In our study, most of the eyes treated with FAc implant remained controlled, with no significant concerns due to IOP changes. About 15% of the patients started IOP lowering medication after implantation which is lower than the reported 18.4% of the IRISS study and 22.0% of the FAME study. These results appear to be in line with other IOP results observed in clinical practice in Europe and below the results reported in FAME studies; with lower IOP increase and a lower surgical rate. Steroid-induced OHT should not be considered a problem as long as patients remain correctly monitored and treated.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.



This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.